

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/912,494	07/24/2001	Thoedore M. Wong	SP-1093.2	7897
7	590 10/14/2003		EXAM	INER
Richard B. Taylor			WARE, DEBORAH K	
Protein Technologies International, Inc.			ART UNIT	PAPER NUMBER
P.O. Box 8894	0		AKI ONII	PAPER NUMBER
St. Louis, MO 63188			1651	10
			DATE MAILED: 10/14/2003	3 ( (

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Advisory Action	09/912,494	WONG ET AL.				
Advisory Modell	Examiner	Art Unit				
	Deborah K. Ware	1651				
-The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress			
THE REPLY FILED FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.						
PERIOD FOR REPLY [check either a) or b)]						
<ul> <li>a) The period for reply expiresmonths from the mailing</li> <li>b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).</li> </ul>	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing	g date of the final rejecti	on.			
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.						
2. The proposed amendment(s) will not be entered because:						
(a)  they raise new issues that would require further	er consideration and/or search (	see NOTE below);				
(b) they raise the issue of new matter (see Note below);						
(c) they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
<ul><li>(d)  they present additional claims without canceling a corresponding number of finally rejected claims.</li><li>NOTE: .</li></ul>						
3. Applicant's reply has overcome the following reject	tion(s): 35 USC 112, second par	agraph.				
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
5.⊠ The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because: of those reasons on Attachment A.						
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.		o issues which were	e newly			
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we			and an			
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed: None.						
Claim(s) objected to: <u>None</u> .						
Claim(s) rejected: <u>79-86</u> .						
Claim(s) withdrawn from consideration:						
8. The proposed drawing correction filed on is a) approved or b) disapproved by the Examiner.						
9. Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s)						
10. Other:						

Application/Control Number: 09/912,494

Art Unit: 1651

## Attachment A

Claims 79-86 are presented for reconsideration on the merits.

The after final amendment filed August 7, 2003, has been received and will be entered.

Art Rejections under 35 USC 102 and 103

The arguments that the claims are not inherently anticipated by the '343 patent are noted, however, the soy protein materials of the cited reference have been treated with a phytase and acid phosphatase which degrade RNA present in soy protein. Therefoere, a soy protein material containing at most 4000 mg/kg RNA is a necessary consequence of such treatment. The treatment with a phytase and acid phosphatase being deliberately intended as disclosed by the prior art reference. With respect to the arguments based on an obviousness rejection over the '343 patent and that there is no disclosure at all relating to degrading RNA, it should be noted that the content of soy protein is well known in the art to contain RNA and that the teaching of RNA is encompassed by the teaching of soy protein of which contains the RNA. Thus, a basis for obviouness is well established by what is conventional and well known in the art as well as what is specifically taught by the cited prior art. In response to applicant's argument that the examiner's conclusion of obviousness is based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the Application/Control Number: 09/912,494

Art Unit: 1651

time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See In re McLaughlin, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). Furthermore, Applicants' exhibits and declaration under 37 CFR 1.132 are noted. However, it is unclear that natuphos is an acid phosphatase and it does not appear to be one. The cited prior art teaches an acid phosphatase which will degrade polymeric ribonucleoside-containing compounds such as RNA. For these reasons and those of record the claims remain rejected over the cited prior art, however, the rejection under 35 USC 112, second paragraph has been removed.

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Deborah K. Ware whose telephone number is 308-4245. The examiner can normally be reached on 9:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on 308-4743. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 308-0196.

October 11, 2003

DAVID M NA PRIMARY EXAM